Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRO I.V. vs METROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Treatment of intra-abdominal infections (e.g., peritonitis, abscess),Treatment of pelvic inflammatory disease,Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (intestinal and extraintestinal),Treatment of anaerobic infections (e.g., bone and joint, central nervous system, respiratory tract, skin and soft tissue),Perioperative prophylaxis (colorectal surgery),Off-label: Helicobacter pylori eradication (with other agents), rosacea (topical), Crohn's disease (perianal fistulas)
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Metronidazole is extensively metabolized in the liver via oxidation and glucuronidation. The major metabolic pathways involve hydroxylation and side-chain oxidation, mediated by CYP450 enzymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4). The primary metabolites are 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-acetic acid, which have minimal antimicrobial activity.
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
<20%, primarily to albumin.
Less than 20%; albumin.
0.6-0.7 L/kg; indicates extensive distribution into tissues including CSF and abscess cavities.
0.25-0.85 L/kg; extensive tissue distribution including CSF.
Oral: 80-90%; IV: 100%.
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
Cr Cl > 50 m L/min: no adjustment; Cr Cl 10-50 m L/min: increase dosing interval to every 12 hours; Cr Cl < 10 m L/min: increase interval to every 24 hours.
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75%.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Loading dose: 15-30 mg/kg IV; maintenance: 7.5 mg/kg IV every 6 hours. For neonates < 7 days: 15 mg/kg IV every 24 hours; 7-28 days: 15 mg/kg IV every 12 hours.
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
Use with caution; adjust dose based on renal function (Cr Cl) and monitor for neurotoxicity. Start at lower end of dosing range.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. It should be used only for approved indications and for the shortest duration necessary.
No FDA black box warning.
Carcinogenicity: Avoid unnecessary use,Peripheral neuropathy: Risk with high doses or prolonged treatment; discontinue if signs occur,Central nervous system effects: Encephalopathy, convulsions, aseptic meningitis; discontinue if symptoms develop,Hepatotoxicity: Risk of severe hepatic injury, including acute liver failure; monitor liver function,Blood dyscrasias: Leukopenia, neutropenia; caution in patients with history of blood disorders,Interaction with alcohol: Disulfiram-like reaction (nausea, vomiting, flushing); avoid alcohol during therapy and for at least 3 days after,Cochrane interaction: Increased INR with warfarin; monitor INR,Renal impairment: Accumulation of metabolites; dosage adjustment may be needed,Prolonged therapy: Monitor for superinfection and neurological symptoms
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (unless alternative treatments not available),Breastfeeding (withhold nursing for 12-24 hours after dose),Concurrent use of disulfiram (psychotic reactions may occur),Severe hepatic impairment (metronidazole is hepatically cleared)
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
No significant food interactions. However, alcohol is strictly contraindicated. Use alcohol-free formulations of medications and avoid alcoholic beverages.
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
Excreted in breast milk in low concentrations; M/P ratio approximately 1.0. Considered compatible with breastfeeding; monitor infant for diarrhea or candidiasis.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
No specific dose adjustment required in pregnancy; pharmacokinetics not significantly altered. Use standard dosing based on infection severity and renal function.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
METRO I. V. (metronidazole) is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It has excellent bioavailability following intravenous administration. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). May cause metallic taste, which is benign. Use with caution in patients with CNS disorders due to risk of seizures.
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Do not drink any alcohol or take products containing alcohol (e.g., mouthwash, cough syrup) while using this medication and for 48 hours after stopping, as it can cause severe nausea, vomiting, headache, and abdominal cramps.,May cause a metallic or bitter taste in the mouth; this is harmless and temporary.,Report any numbness, tingling, or weakness in your arms or legs to your healthcare provider immediately, as this could be a sign of nerve damage.,Take the full course of therapy exactly as prescribed, even if you feel better.,If you have severe liver disease, your dose may need to be adjusted.
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRO I.V. vs METROGEL, answered by our medical review team.
METRO I.V. is a Antibiotic (Nitroimidazole) that works by Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.. METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRO I.V. and METROGEL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRO I.V. is: 15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.. The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRO I.V. and METROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRO I.V. is classified as Category C. Pregnancy category B. No evidence of teratogenicity in human studies; crosses placenta. Avoid during first trimester unless benefit outweighs risk; use only if clearly needed.. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.